NEW YORK (GenomeWeb) – Affymetrix and UK-based XRGenomics are collaborating on the development of new diagnostic tests for neurodegenerative diseases, the companies said today.

Financial and other terms of the agreement were not disclosed.

XRGenomics has used Affymetrix's GeneTitan microarray technology to develop gene expression signatures and find biomarkers for diseases such as Alzheimer's disease.

The firm plans to use the technology to optimize its RNA signatures in large clinical trials involving thousands of patients with cognitive impairment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.